
New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
18.6.2026
0:00
22:49
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more.
Related Content:
Weitere Episoden von „JAMA Medical News“



Verpasse keine Episode von “JAMA Medical News” und abonniere ihn in der kostenlosen GetPodcast App.








